Last update Oct. 21, 2023
Compatible
We do not have alternatives for Agalsidase Alfa. Agalsidase Beta since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Agalsidase Alfa. Agalsidase Beta is also known as
Agalsidase Alfa. Agalsidase Beta in other languages or writings:
Agalsidase Alfa. Agalsidase Beta belongs to these groups or families:
Main tradenames from several countries containing Agalsidase Alfa. Agalsidase Beta in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | ≈ 0 | % |
Molecular weight | 45.352 | daltons |
Protein Binding | 0 | % |
VD | 0.003 (0.001 - 0.1) | l/Kg |
T½ | 0.7 - 1.7 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Agalsidases alpha and beta are similar recombinant forms of the endogenous enzyme alpha galactosidase A. Their amino acid sequence is identical to that of the natural enzyme. They are used to treat by enzyme replacement Fabry disease, a lysosomal deposit disease caused by a genetic deficiency in the enzyme alpha-galactosidase A, which leads to the accumulation of glycosphingolipids such as globotriaosylceramide in the walls of blood vessels and smooth muscle. Administration by intravenous infusion every two weeks. Alpha galactosidase alfa has been used orally to reduce intestinal gas production (Di Stefano 2007).
At the time of the last update, we found no published data on its excretion in breast milk.
Its high molecular weight makes it unlikely to be excreted in breast milk in significant quantities.
Due to its protein nature, it is inactivated in the gastrointestinal tract, not being absorbed (oral bioavailability practically null), which prevents its passage into infant plasma from ingested breast milk, except in premature infants and immediate neonatal period, in which there may be greater intestinal permeability.
No treatment-related adverse effects were observed in six infants of mothers treated with agalsidase alfa. (Fernández 2019)